PT  - JOURNAL ARTICLE
ED  - Vidt, Donald G.
AU  - Mandell, Brian F.
TI  - COX 2-selective NSAIDs: Biology, promises, and concerns
DP  - 1999 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 285--292
VI  - 66
IP  - 5
4099  - http://www.ccjm.org/content/66/5/285.short
4100  - http://www.ccjm.org/content/66/5/285.full
SO  - Cleve Clin J Med1999 May 01; 66
AB  - Celecoxib (Celebrex) is the first of a new family of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit cydooxygenase 2 (COX 2) while sparing COX 1. Clinical trials indicate that it is approximately as effective in relieving the pain of osteoarthritis and the pain and inflammation of rheumatoid arthritis as nonselective NSAIDs, but causes less gastrointestinal ulceration and bleeding. This paper reviews the pharmacology and possible clinical role of celecoxib and other COX 2-selective NSAIDs.